Leading the Way in Life Science Technologies

GEN Exclusives

More »

Tutorials

More »
Jan 15, 2010 (Vol. 30, No. 2)

Outsourcing Bioproduction Processes

Right Partner Can Provide a Number of Benefits Including Flexibility and Cost Reduction

  • Case Study 2

    Click Image To Enlarge +
    Figure 1B. 50 L fed-batch S.U.B. culture of Sf9 cells for VLP production by BEVS

    Insect cell culture supporting baculovirus-based expression has been finding more utility in recent years, specifically in viral vaccines. A second study was initiated to develop an animal product-free feeding protocol that would support peak culture densities in excess of 30 million cells/mL in a disposable culture system. The results presented show the application of optimized feed solutions in the fed-batch culture of Sf9 cells using a Thermo Scientific HyClone S.U.B. in Thermo Scientific HyClone SFM4Insect. Peak cell densities in excess of 35 million cells/mL were obtained in well-behaved and scalable disposable systems (Figure 1B).

    Many factors are affecting the technologies and expertise required in bioprocess development or optimization, which increases the potential benefits of outsourcing. Both the particular project demands, as well as the existing capabilities and strategic goals of the sponsor company, determine what capabilities should be sought in an outside partner. 

    In general, a good partner is an international company with a solid business and financial history. More specific criteria include possession of relevant analytics and subject-mater experts, appropriate regulatory certification or license, and demonstrated experience in the operation of interest. But, there are often desirable considerations such as process materials manufacturing and distribution capability, which while ancillary to the project at hand, can contribute to the ultimate economy of the contracted activities.

  • Click Image To Enlarge +
  • Click Image To Enlarge +
  • Click Image To Enlarge +


Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »